二硫胺盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 二硫胺盐酸盐
• 英文名称: N,N'-((2Z,2'Z)-dithiodimethylbis(5-hydroxypent-2-en-3,2-diyl)bis(N-(4-amino-2-methylpyrimidin-5-yl)methyl)formamide) dihydrochloride
• 英文别名: bis-{2-[(4-amino-2-methyl-pyrimidin-5-ylmethyl)-formyl-amino]-1-(2-hydroxy-ethyl)-trans-propenyl}-disulfide; dihydrochloride；Bis-{2-[(4-amino-2-methyl-pyrimidin-5-ylmethyl)-formyl-amino]-1-(2-hydroxy-aethyl)-trans-propenyl}-disulfid; Dihydrochlorid；N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(Z)-3-[[(Z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide;hydron;chloride
• 化学式: C₂₄H₃₄N₈O₄S₂*2ClH
• 分子量: 635.639
• InChiKey: VFKAKLWCYOVTIN-LBQDPBSMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  39
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  235
• 氢给体数：
  5
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  DL-半胱氨酸 、 二硫胺盐酸盐 在 水 作用下， 生成 N-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-N-(4-hydroxy-2-mercapto-1-methyl-but-1-en-t-yl)-formamide; hydrochloride
  参考文献：
  名称：

  Zima et al., Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1940, vol. 267, p. 210,212,214

  摘要：

  DOI：
• 作为产物：
  描述：

  thiamine disulfide 在 盐酸 作用下， 以 甲醇 、 异丙醇 为溶剂， 生成 二硫胺盐酸盐
  参考文献：
  名称：

  含硫类化合物、其药物组合物及应用

  摘要：

  本发明公开了一种含硫类化合物、其药物组合物及应用。本发明提供了一种物质A在制备Aβ40和/或Aβ42蛋白抑制剂或药物中的应用；所述的药物为用于治疗和/或由Aβ40和/或Aβ42蛋白介导的疾病的药物或者用于治疗和/或预防神经退行性疾病或衰老的药物，所述的物质A选自如式A1等所示的化合物或其药学上可接受的盐。本发明的化合物，对Aβ40及Aβ42蛋白具有良好的抑制作用，有望治疗和/或预防神经退行性疾病或衰老药物。#imgabs0#

  公开号：

  CN117417301A

文献信息

• Therapeutic formulations for the treatment of beta-amyloid related diseases
  申请人：Gervais Francine

  公开号：US20050031651A1

  公开（公告）日：2005-02-10

  This invention relates to methods and pharmaceutical compositions for treating amyloid-β related diseases, including Alzheimer's disease. The invention, for example, includes a method of concomitant therapeutic treatment of a subject, comprising administering an effective amount of a first agent and a second agent, wherein said first agent treats an amyloid-β disease, neurodegeneration, or cellular toxicity; and said second agent is a therapeutic drug or nutritive supplement.

  本发明涉及治疗淀粉样蛋白-β相关疾病（包括阿尔茨海默病）的方法和药物组合物。例如，本发明包括一种同时治疗受试者的方法，包括施用有效量的第一种药剂和第二种药剂，其中所述第一种药剂治疗淀粉样蛋白-β疾病、神经变性或细胞毒性；所述第二种药剂是治疗药物或营养补充剂。
• 一种含硫类化合物及其药物组合物
  申请人：上海日馨医药科技股份有限公司

  公开号：CN116531381A

  公开（公告）日：2023-08-04

  本发明公开了一种含硫类化合物、其药物组合物及应用。本发明提供了一种含硫类化合物或其药学上可接受的盐在用于制备药物中的应用，所述的药物为用于治疗和/或预防由Aβ40和/或Aβ42蛋白介导的疾病的药物或者用于治疗和/或预防神经退行性疾病、阿尔茨海默病或衰老的药物，所述含硫类化合物选自如下式I所示含硫类化合物或式II所示含硫类化合物。本发明的化合物，对Aβ40及Aβ42蛋白具有良好的抑制作用，有望治疗和/或预防神经退行性疾病，阿尔茨海默病或衰老药物。
• THERAPEUTIC FORMULATIONS FOR THE TREATMENT OF BETA-AMYLOID RELATED DISEASES
  申请人：Neurochem (International) Limited

  公开号：EP1841460A2

  公开（公告）日：2007-10-10
• Compositions and method for treatment of chronic inflammatory diseases
  申请人：Shapiro K. Howard

  公开号：US20050090553A1

  公开（公告）日：2005-04-28

  This invention defines novel compositions that can be used for clinical treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, namely aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clinical disorders addressed herein. Such carbonyl substances are cytotoxic and additionally serve to perpetuate and disseminate the inflammatory process. This invention defines use of compositions, the orally administered required primary agents of which are primary amine derivatives of benzoic acid capable of covalently reacting with the carbonyl substances. p-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed therapeutically effective amount of at least one required primary agent; (2) at least one required previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally one or more additional orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and nonabsorbable primary amine polymeric co-agents, so as to produce an additive or synergistic physiological effect of an anti-inflammatory nature.
• US6746678B1
  申请人：——

  公开号：US6746678B1

  公开（公告）日：2004-06-08